22. Immune responses to malignancies - 29/08/11
Abstract |
Immune responses to tumor-associated antigens exist in tumor-bearing hosts but are usually not successful in eliminating malignant cells or preventing the development of metastases. Patients with cancer generate robust immune responses to infectious agents (bacteria and viruses) perceived as a “danger signal” but only ineffective, weak responses to tumor-associated antigens, which are considered as “self.” This fundamental difference in responses to self versus non-self is further magnified by the ability of tumors to subvert the host immune system. Tumors induce dysfunction, as well as apoptosis in CD8+ antitumor effector cells. The escape of tumors from immune cells is mediated by several distinct molecular mechanisms. Insights into these mechanisms and more effective control of tumor-orchestrated immune dysfunction are needed. Novel strategies for immunotherapy of cancer must address protection and survival of antitumor effector cells in the tumor microenvironment. (J Allergy Clin Immunol 2003;111:S677-86.)
Le texte complet de cet article est disponible en PDF.Keywords : Cancer, immunity, apoptosis, immune suppression, effector T cells
Abbreviations : Anx, APC, CTL, DC, DTH, ECM, LAK, MHC, NK, NFκB, PBL, RCC, ROM, RTE, TADC, TAM, TCR, TIL, TNF, TREC, VEGF, ZIP
Plan
| Supported in part by NIH grants PO1-DE 12321 and RO1-DE 13918. |
|
| Reprint requests: Theresa L. Whiteside, PhD, University of Pittsburgh Cancer Institute, Research Pavilion at the Hillman Cancer Center, Suite 1.27, 5117 Centre Ave, Pittsburgh, PA 15213-1863. |
Vol 111 - N° 2S2
P. S677-S686 - février 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
